Ultivue by Vizgen

Two leaders. One vision. The next stage in the evolution of spatial biology is here. Vizgen and?Ultivue by Vizgen?have joined forces to unleash the full potential of spatial multi-omics and unlock new possibilities in biological discovery, biomarker development, and clinical translation. Together, we’re shaping a future where transcriptomics and proteomics are seamlessly integrated into a next-generation, comprehensive multi-omics solution. Join us at AGBT to talk science, innovation, and what’s next! Message us on the conference app to connect and book a meeting with our executive team. #AGBT25 #SpatialMultiOmics #SpatialGenomics

Meet us at #JPM25 to explore new solutions advancing biopharma’s next frontier. Vizgen will be at JP Morgan Healthcare Conference 2025 discussing how our InSituPlex? assays along with MERSCOPE? and STARVUE? platforms for high-fidelity multiomic tissue analysis facilitate biopharma innovation in advanced modalities including ADCs and CGTs. Let’s meet to explore how Vizgen’s solutions can empower your translational and clinical research. ?? Book a meeting with our CEO, Rob Carson, here: https://hubs.ly/Q0322bHD0 #SpatialMultiomics #Biopharma #JPM2025 #ADC #CGT

Season's Greetings and Happy New Year from the Ultivue by Vizgen team! As we reflect on a momentous year, we’re inspired by the incredible scientific breakthroughs our customers and partners are achieving and are honored to be a part of enabling your bold visions to become reality. This year, we celebrated the launch of our 12-plex OmniVUE? panels and STARVUE? spatial image data science pipeline. We’re also excited by the transformative journey we’ve embarked on through our merger with Vizgen which will empower deeper insights into disease mechanisms and drive innovation at the forefront of spatial multi-omics. Together, we’re advancing scientific discovery in ways that will shape the future of precision medicine and improve patient outcomes. Today and every day, we are filled with gratitude for our global customers, partners, colleagues and friends for your trust, collaboration, and shared passion for advancing science. We wish you joy, health and a bright start to 2025! Ultivue by Vizgen will be closed on New Year’s Day in observance of the holiday.

Exciting news: The Ultivue STARVUE? AI-driven image data science platform is one of The Scientist's Top 10 Innovations of 2024! This recognition underscores the ingenuity and impact STARVUE is bringing to spatial biology, empowering researchers to explore robust spatial insights at unprecedented scale and resolution. Scott Daigle of Nimbus Therapeutics describes to The Scientist how STARVUE is helping him and his team accelerate drug development and validate their clinical prognosis: “We can get majority of our answers just from this one assay… Are those T cells engaging with the cancer cells, are they activated, are they doing as we expected? Tissues from clinical samples are extremely precious, and so to be able to multiplex and get that type of data is great.” The Scientist’s annual Top 10 Innovations competition “showcases the most transformative and useful advances in life science techniques and products.” We’re honored to see STARVUE celebrated alongside other groundbreaking innovations shaping the future of science, medicine and discovery and congratulate our fellow honorees. Learn more in this article from The Scientist: https://hubs.ly/Q02_BKpH0 #SpatialBiology #SpatialMultiOmics #Innovation #AI

Scenes from the 39th Society for Immunotherapy of Cancer (SITC) annual meeting: We were thrilled to connect with industry partners and colleagues to introduce Vizgen’s expanded capabilities and latest advances in spatial multi-omics.?? ? Our four presentations highlighted the strength and impact of Vizgen’s portfolio of spatial biology innovations. ? ? A special ‘thank you’ to Scott Daigle, Sr. Director of Translational Medicine at Nimbus Therapeutics, for presenting new research findings and a case study demonstrating how our ultrasensitive InSituPlex? assays and the STARVUE? AI-driven image analysis platform are validating their clinical prognosis and accelerating drug development.?? ? Congratulations to our partners at Hamamatsu Corporation on the launch of the new MoxiePlex platform for multiplex fluorescent tissue imaging. The new platform integrates user-friendly and robust spatial proteomics through InSituPlex assays with industry-leading utility, speed, precision, and scalability. Thank you, Carlo Bifulco and Don Ariyakumar M.S , MBA. ? ?? See you next year at SITC! #SpatialBiology #MultiOmics

?? Reminder: Join Vizgen at the Society for Immunotherapy of Cancer (SITC) 2024 for our symposium presentation with Nimbus Therapeutics on Saturday, Nov. 9 at 12:30 pm in Room 320C. Nimbus will share new research findings and a case study demonstrating how our ultrasensitive InSituPlex? assays and the STARVUE? AI-driven image analysis platform are validating their clinical prognosis and accelerating drug development. Nimbus will also present new data from their Phase 1/2 clinical trial of an HPK1 inhibitor for treatment of advanced solid tumors. Symposium Presentation Details: Title: “Evaluating Treatment Efficacy and Tumor Immune Contexture with InSituPlex? and STARVUE? Technologies” Presenters: Scott Daigle, Sr. Director of Translational Medicine at Nimbus Therapeutics, and Angela Vasaturo, Director of Scientific Affairs at Vizgen Vizgen scientists will also present three posters demonstrating the capabilities of the company’s portfolio of leading spatial biology solutions for advancing immunotherapy research. ?? Details: https://hubs.ly/Q02Xw4D50 We look forward to seeing you there!

"Vizgen cemented its leadership spot among private spatial biology companies on October 9, when it announced a merger with Ultivue."? We couldn't agree more! We’re excited to share that Vizgen has once again been named Genetic Engineering & Biotechnology News’ #1 private spatial biology company —an exciting milestone on the heels of the Vizgen-Ultivue merger. Through the combination of Vizgen’s strengths in single-cell spatial genomics and Ultivue’s leadership in multiplex proteomic profiling, we’re now uniquely equipped to deliver a unified spatial multi-omics solution to our customers, opening new doors for researchers and helping to unlock new opportunities for innovation in discovery and clinical development.?Here’s to pushing the boundaries of what’s possible in spatial biology! Read more in GEN:?https://lnkd.in/gNMTn6_M

??Join Vizgen, recently merged with Ultivue, at Society for Immunotherapy of Cancer (SITC) 2024 to explore new breakthroughs in spatial biology for immunotherapy.? We’re looking forward to presenting new research findings and a case study with?Nimbus Therapeutics demonstrating?how Nimbus utilizes ultrasensitive InSituPlex? assays and the STARVUE? AI-driven image analysis platform to validate their clinical prognosis and accelerate drug development. ??See new data from Nimbus’ Phase 1/2 clinical trial of an HPK1 inhibitor for treatment of advanced solid tumors. ??Learn?how InSituPlex? reduces assay development times, streamlining the path from validation to results. ??Explore?high-precision biomarker detection in action, enabling robust and actionable insights through deep-learning models. ???Symposium Presentation: Saturday, Nov. 9, 2024?| 12:30–1:30 p.m.?|?Room 320 C “Evaluating Treatment Efficacy and Tumor Immune Contexture with InSituPlex? and STARVUE? Technologies” Presenters:? Scott Daigle, Sr Director of Translational Medicine, Nimbus Therapeutics Angela Vasaturo, Director of Scientific Affairs, Vizgen? Vizgen scientists will also present three posters demonstrating the capabilities of the company’s portfolio of leading spatial biology solutions.? Details on each presentation are below and here: https://hubs.ly/Q02W7mfZ0 We hope to see you at SITC!

Join us at the Spatial Biology for Drug Development Summit to discover how OmniVUE? modular biomarker panels accelerate precision oncology research with flexible panel assembly for rapid and agile investigation of tumor spatial biology. On October 23 at 1:45pm ET, Yvette Cajigas will present: “Demonstrating Robustness and Phenotypic Diversity with OmniVUE?: A Customizable Multiplex Immunofluorescence Platform.” Learn how the OmniVUE? modular multiplex panels help reduce assay development timelines from months to weeks with our continuously expanding core library of more than 24 validated, clinically relevant biomarkers for clinical-grade assay performance and barcode amplification. Yvette will also demonstrate how our InSituPlex? assays’ proprietary signal amplification delivers more insights from a single slide while visualizing up to 12 biomarkers simultaneously–including T-cell, macrophage and tumor markers–with unprecedented consistency and high dynamic range. See how the platform detects complex tumor phenotypes from a single sample so that precious specimens can be preserved for future analyses. We hope to see you there! Reach out to us to schedule a meeting via our website or email us at [email protected].

“The combined company—which will carry the Vizgen name—will build upon its namesake predecessor’s expertise in single-cell spatial genomics and Ultivue’s leadership in multiplex proteomic profiling. The new Vizgen also aims to increase its presence in clinical lab settings while continuing to serve customers in research institutions and biopharmas.” In Genetic Engineering & Biotechnology News, learn more about what this week’s Ultivue-Vizgen merger means for the field of spatial multi-omics and the future of precision medicine: https://hubs.ly/Q02T1r3y0